WA
VRTX icon

Whitebox Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

Whitebox Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-13,224
Closed -$1.63M – 390
2015
Q2 		$1.63M Buy
13,224
+15
+0.1% +$1.89K 0.07% 220
2015
Q1 		$1.56M Buy
+13,209
New +$1.58M 0.06% 214

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Whitebox Advisors's VRTX Position: Q3 2015 in Review

Whitebox Advisors sold out of Vertex Pharmaceuticals (VRTX) in Q3 2015, closing a stake of 13,224 shares — an estimated $1.63M sold.

Whitebox Advisors first reported a position in VRTX in Q1 2015 and held it in 2 quarters. The position peaked at $1.63M in Q2 2015. 493 funds tracked by Wall St. Rank hold VRTX as of Q3 2015.

  • Whitebox Advisors reported no remaining Vertex Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Whitebox Advisors sold 13,224 Vertex Pharmaceuticals shares in Q3 2015, an estimated $1.63M.
  • Whitebox Advisors first reported a position in Vertex Pharmaceuticals in Q1 2015 and held it in 2 quarters.
  • Whitebox Advisors's Vertex Pharmaceuticals position peaked at $1.63M in Q2 2015.
  • 493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2015.

Based on Whitebox Advisors's 13F filing for Q3 2015, filed 12 Nov 2015.